Gelesis Holdings (Gelesis Holdings) Profitability Rank : 0 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings Profitability Rank?

Gelesis Holdings has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Gelesis Holdings's Operating Margin % for the quarter that ended in Jun. 2023 was -902.98%. As of today, Gelesis Holdings's Piotroski F-Score is 9999.

Competitive Comparison of Gelesis Holdings's Profitability Rank

For the Biotechnology subindustry, Gelesis Holdings's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's Profitability Rank falls into.

Gelesis Holdings Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Gelesis Holdings has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Gelesis Holdings's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-9.996	/	1.107
	=	-902.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Gelesis Holdings has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank

Gelesis Holdings Profitability Rank Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » Profitability Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Executives

Raju S Kucherlapati	director	77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc	10 percent owner	195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd	10 percent owner	SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino	officer: Lead Project Scientist	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks	director	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass	officer: Chief Op. & Comm. Officer	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette	officer: Chief Scientific Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman	director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider	officer: Chief Medical Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher	director	2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech	10 percent owner	6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc	10 percent owner	142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar	director, officer: President & CEO	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms	10 percent owner	C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510